Centromere Replication Defects Underlie Mitotic Catastrophe in Topoisomerase II Inhibitor-Induced Checkpoint Override

Topoisomerase II (topoII) inhibitors such as doxorubicin and etoposide are widely used in cancer chemotherapy due to their ability to induce DNA double-strand breaks. However, recent findings indicate that their cytotoxic effects extend beyond simple DNA damage—they also disrupt centromere replication, a critical process for faithful chromosome segregation. This study demonstrates that topoII inhibition leads to unreplicated centromeres, which become the primary source of mitotic catastrophe when cells are forced into premature mitosis via checkpoint override.

Using fluorescence in situ hybridization (FISH) with a chromosome 7-specific probe targeting α-satellite DNA, we found that a significant proportion of cells treated with doxorubicin or etoposide displayed only a single FISH signal, despite having a 4N DNA content—indicating that centromeres had not undergone replication. In contrast, cells arrested with the alkylating agent MMS consistently showed duplicated signals, confirming that centromere replication proceeds normally under this type of damage. These results suggest that topoII plays a unique role in centromere duplication, likely by resolving topological constraints during replication of repetitive centromeric sequences.

To determine whether unreplicated centromeres alone could trigger mitotic catastrophe, we performed a key experiment: cells were first arrested in G2 with MMS, then treated with either gemcitabine or doxorubicin for one hour before Chk1 inhibition with UCN-01.1,3-Di(2-pyridyl)-1,3-propanedione manufacturer While both agents caused DNA damage, only doxorubicin-treated cells generated fragmented chromosomes and dissociated kinetochores upon mitotic entry.Annulatin Purity & Documentation Normal metaphases were observed in gemcitabine-treated cells, indicating that strand breaks alone do not produce MUGs. This confirms that the lethal outcome is not due to general DNA fragmentation but specifically to the failure of centromere replication.

Ultrastructural analysis via electron microscopy revealed C-shaped kinetochore fragments detached from chromatin mass—identical to those seen in MUGs generated by S phase arrest. Immunofluorescence further confirmed that centromere proteins such as CENP-A and ACA were no longer associated with chromatin but instead localized independently within the spindle midzone. Biochemical fractionation of mitotic lysates demonstrated enrichment of kinetochore components in low-density fractions, providing physical evidence of centromere–chromatin dissociation.

These findings establish that topoII inhibitors generate a unique form of genomic stress: they block the replication of centromeric DNA without inducing immediate DNA strand breaks.PMID:35134684 When checkpoint control is abrogated, cells enter mitosis with unreplicated centromeres, resulting in acentric chromosomes that cannot attach to microtubules or segregate properly. The consequence is catastrophic chromosome missegregation, leading to cell death.

This mechanism explains why topoII inhibitors are particularly effective chemosensitizers when combined with Chk1 inhibitors. Unlike gemcitabine, which causes variable responses across cell lines due to differences in S phase checkpoint competence, topoII inhibitors consistently impair centromere replication regardless of cellular context. Therefore, therapies combining topoII inhibitors with checkpoint inhibitors should be prioritized for clinical development, especially in tumors where resistance to S phase-targeting agents is common. Ultimately, targeting centromere replication represents a powerful strategy to amplify the lethality of checkpoint override and improve therapeutic outcomes in cancer treatment.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com